Evidence map›Paper›PMID 25742654›Full record

ArticlePloS one2015

An ex vivo model for anti-angiogenic drug testing on intact microvascular networks.

Mohammad S Azimi, Leann Myers, Michelle Lacey, Scott A Stewart, Qirong Shi, Prasad V Katakam, Debasis Mondal, Walter L Murfee

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Understanding angiogenesis during aging: opportunities for discoveries and new models.Journal of applied physiology (Bethesda, Md. : 1985) · 2018
    Review
  11. Induction of microvascular network growth in the mouse mesentery.Microcirculation (New York, N.Y. : 1994) · 2018
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mohammad S AzimiDepartment of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Leann MyersDepartment of Biostatistics & Bioinformatics, Tulane University, New Orleans, Louisiana, United States of America.
Michelle LaceyDepartment of Mathematics, Tulane University, New Orleans, Louisiana, United States of America.
Scott A StewartDepartment of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Qirong ShiDepartment of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Prasad V KatakamDepartment of Pharmacology, Tulane University, New Orleans, Louisiana, United States of America.
Debasis MondalDepartment of Pharmacology, Tulane University, New Orleans, Louisiana, United States of America.
Walter L MurfeeDepartment of Biomedical Engineering, Tulane University, New Orleans, Louisiana, United States of America.
Tulane University · US

Funding

The role of the CMV-associated reactive oxygen species in age-relatedP20GM103629 · NIGMS · TULANE UNIVERSITY OF LOUISIANA · PI ROUT, NAMITA · 2012 to 2021
$22.4M
NIGMS NIH HHS 5-P20GM103629-02NIGMS NIH HHS P20 GM103629
6 · The paper itself

Abstract

New models of angiogenesis that mimic the complexity of real microvascular networks are needed. Recently, our laboratory demonstrated that cultured rat mesentery tissues contain viable microvascular networks and could be used to probe pericyte-endothelial cell interactions. The objective of this study was to demonstrate the efficacy of the rat mesentery culture model for anti-angiogenic drug testing by time-lapse quantification of network growth. Mesenteric windows were harvested from adult rats, secured in place with an insert, and cultured for 3 days according to 3 experimental groups: 1) 10% serum (angiogenesis control), 2) 10% serum + sunitinib (SU11248), and 3) 10% serum + bevacizumab. Labeling with FITC conjugated BSI-lectin on Day 0 and 3 identified endothelial cells along blood and lymphatic microvascular networks. Comparison between day 0 (before) and 3 (after) in networks stimulated by 10% serum demonstrated a dramatic increase in vascular density and capillary sprouting. Growing networks contained proliferating endothelial cells and NG2+ vascular pericytes. Media supplementation with sunitinib (SU11248) or bevacizumab both inhibited the network angiogenic responses. The comparison of the same networks before and after treatment enabled the identification of tissue specific responses. Our results establish, for the first time, the ability to evaluate an anti-angiogenic drug based on time-lapse imaging on an intact microvascular network in an ex vivo scenario.

Indexed as

Models, BiologicalAngiogenesis InhibitorsAnimalsBevacizumabEndothelial CellsIndolesIn Vitro TechniquesMaleMesenteric ArteriesMicroscopyMicrovesselsPyrrolesRatsRats, WistarSunitinibTime-Lapse ImagingAngiogenesis InhibitorsBevacizumabIndolesPyrrolesSunitinib

Identifiers

PMID25742654
PMCPMC4350846
OpenAlexW2052843353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.